Biotechnology is a unique science which deals with the modification of natural processes and living organisms. The intellectual property rights regime, around the world has transformed through the growth of research and development undertaken in the field of biotechnology. Ever since the US Supreme Court granted patent rights to a genetically engineered micro-organism, the field of biotechnology has gained mammoth significance. Further, patents have been granted to genetically engineered plants and human genetic material. With such enormous growth of research in this field, several revolutionary and innovative trends have been adopted in the recent times, which has resulted in new found challenges for authorities granting patents. The nature of the field prevents the application of an individual generic patent model for the varied classes of biotechnology. This paper will examine and analyse the effectiveness and complexities of patenting biotechnology inventions and existing lacunae in the law.
References
- Bajaj Auto Ltd. v. TVS Motor CO., 2008 ILLJ 726 Mad
- Parke-Davis vs. H.K. Mulford 189 F 95 (SDNY 1911)
- Emergent Genetics India Pvt. Ltd v. Shailendra Shivam and Ors, 2011 (125) DRJ 173
- Merck Sharp and Dohme Corporation v. Glenmark Pharmaceuticals, 223(2015) DLT454
- Biswanth Prasad Radhe Shyam v. Hindustan Metal Industries, 1979 2 SCC 511
- F. Hoffmann-La Roche Ltd vs Cipla Ltd, Mumbai Central, 2009 (40) PTC 125 (Del)
- Osi Pharmaceuticals vs Intas Biopharmaceuticals, MIPR2012(1)223
- Diamond vs. Chakrabarty, 447 US 303 (1980).
- Parker vs. Hook, 437 US 584 (1978).
- Brenner vs. Manson, 383 US 519 (1996)
- PHILIP W. GRUBB & PETER R. THOMSEN, PATENTS FOR CHEMICALS, PHARMACEUTICALS, AND BIOTECHNOLOGY, 275-276 (5th ed. 2010)
- P. NARAYANAN, PATENT LAW 1 (4th ed. 2006)
- The Convention on Biological Diversity, Article 2, 1992
- Agreement On Trade-Related Aspects of Intellectual Property Rights, Jan 1st 1995, 1869 UNTS 299; 33 ILM 1197 (1994)
- European Patent Convention, art 54, Oct 15th 1973.
- The European Parliament and of the Council on the Legal Protection of Biotechnological Inventions, Directive 98/44/EC; Article 3(2): “Biological material which is isolated from its natural environment or produced by means of a technical process may be the subject of an invention even if it previously occurred in nature”
- TIFAC, Intellectual Property Rights, Vol.5 No. 8, p6, (1999). (Available at http://www.pfc.org.in/fac/augbul.pdf)
- Office of the Controller General of Patents, Designs and Trade Marks; Guidelines for examination of Biotechnology applications for patent, March 2013. (Available at: http://www.ipindia.nic.in/whats_new/biotech_Guidelines_25March2013.pdf)
- K. Saito & R. Sweeney, Assessment of Inventive Step or Obviousness in the United States, Europe, and Japan, (available at http://www.law.washington.edu/casrip/harmo nization/PDF/obviousness.pdf).
- David V. Radack, GATT Brings Major Changes in U.S. Patent Law, JOM, p. 79, (1995).
- Sivaramjani Thambisetty, Novartis v Union of India and the Person Skilled in the Art: A Missed Opportunity, LSE Law, Society and Economy Working Papers, 2/2014.
- A. Nelson, Obviousness or Inventive Step as Applied to Nucleic Acid Molecules: A Global Perspective, North Carolina Journal of Law and Technology, p.1, 2004.
- Heller, M.A. “The tragedy of Anti-Commons.” Harvard Law Review, January 1, 1998.
- Dr. Kalyan C Kankanala, Complications in Patenting Biotech Inventions., Biotech Patent law, 36. (1st ed. 2007).
- Patents Act, 1970
- Conditions for patentability; novelty, 35 U.S. Code § 102
